Several studies have also reported A*02:01 to be protective against EBV-related Hodgkin’s lymphoma,40-42 likely from a stronger LMP2A (latency II)-specific CD8+ T cell response.43 This may explain the differences in genetic and MS risk associations among IM history and EBNA-1 (latency I–III) and VCAp18 (lytic) serology. This evidence concerns the gene CD8A and myeloid sarcoma.